4 
The representatives of the Department of Defense called to the attention 
of the Committee their concerns about how classified material on possible 
national security grounds might be handled. It was noted that the mandate 
of the Committee does not extend to considerations of national security, 
and it was agreed that this matter is one of importance for the National 
Security Council to address. 
Disclosure of Information 
Debate on this element of the suggested legislation began in the first 
meeting and was concluded at the meeting on March 14. Dr. Ancker-Johnson, 
Commerce Department, proposed a suggested element for legislation concerning 
disclosure of Information that is included in Appendix I. Other proposals 
on the issue by Defense and the Office of the The Assistant Secretary for 
Health (OASH/DHEW) are also Included in Appendix I. Dr. Ancker-Johnson 
explained that her proposal was designed to encourage the investment of 
private risk capital in the commercial development of benefits to be gained 
through recombinant DMA research. In response. Dr. Elder, Food and Drug 
Administration, stated that the emphasis would shift from consideration 
of public health and safety to one of protecting proprietary information. 
It was agreed that the language submitted by Commerce and DOD would achieve 
essentially the same results, but that the former was more specific than 
the latter. Dr. Ancker-Johnson offered the following arguments in support 
of the language submitted by either Dr. Koslov or herself: 
1. the submitter of the proposal is in the best position to 
make the determination of what information is of a proprietary 
nature; 
[ 269 ] 
